Category: Regeneron
-
Munich I Regional Court grants Regeneron preliminary injunctions against Advanz (21 European countries), Celltrion, Hexal, Stada
Regeneron used a patent that previously secured injunctions against Formycon.
-
UPC CoA reverses invalidation of Amgen patent, clarifies standards for added matter and sufficient disclosure; infringement action to resume
In a high-stakes life sciences case, the UPC’s CoA has provided its most far-reaching clarifications on (in)validity to date.
-
Munich I Regional Court’s written reasons for multi-country pharma PI: out-of-district defendants can be sued, German procedures apply
The Munich I Regional Court’s headnotes are highly instructive and make the court an attractive forum for cross-border injunctions.
-
Munich I Regional Court’s stunning PI for 20+ countries: based on BSH, doctrine of equivalents, difficult-to-enforce formulation patent
Munich has been a patent injunction hotspot for many years, and the latest development may attract even more litigation to the venue.